Flynn LL, Mitrpant C, Pitout IL, Fletcher S, and Wilton SD, Antisense oligonucleotide mediated terminal intron retention of the SMN2 transcript. Mol Ther Nucleic Acids, 2018. (in press).

Martinovich KM, Shaw NC, Kicic A, Schultz A, Fletcher S, Wilton SD, and Stick SM, The potential of antisense oligonucleotide therapies for inherited childhood lung diseases. Mol Cell Pediatr, 2018. 5(1): p. 3.

Martinovich KM, Shaw NC, Kicic A, Schultz A, Fletcher S, Wilton SD, and Stick SM, The potential of antisense oligonucleotide therapies for inherited childhood lung diseases. Mol Cell Pediatr, 2018. 5(1): p. 3.

Targeted alternative splicing: a common therapeutic platform to treat inherited diseases. Wilton, Fletcher, Zheng, Mastaglia. 2018-2020 $798,165. NHMRC Application 114479.1

Stargardt disease. Chen, de Roach, Hunt and Wilton. 2018-2019 $120,000. Macular Disease Foundation.

Translational development of splice-modifying antisense oligomers Fletcher S, Bellgard MI, Price L, Akkari AP, Wilton SD 2017 Expert Opin Biol Ther 17: 15-30

A Dominant-Negative COL6A1 Pseudoexon Insertion Is Skippable Using Splice-Modulating Oligonucleotides Bolduc V, Foley AR, Donkervoort S, Hu Y, Cummings BB, Lek M, Sarathy A, Sizov K, Degefa HS, Wagener R, Hennig GW, Hanssen E, Lamande SR, Muntoni F, Wilton SD, Macarthur DG, Bonnemann CG 2017 Molecular Therapy 25: 119-120

Le BT, Adams AM, Fletcher S, Wilton SD, and Veedu RN (2017) Rational design of short locked nucleic acid-modified 2’-O-methyl antisense oligonucleotides for efficient exon-skipping in vitro. Molecular Therapy – Nucleic Acids, 9, 155–161. doi: 10.1016/j.omtn.2017.09.002 [Rank: Q1; Cell Press]